Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2009-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2009.03.008PMID 19328688
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.

  2008cited by this paper
• Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation

  2008cited by this paper
• FXR: a promising target for the metabolic syndrome?

  2007cited by this paper
• Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.

  2007cited by this paper
• Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

  2006cited by this paper
• FXR, a multipurpose nuclear receptor.

  2006cited by this paper
• The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice*

  2006cited by this paper
• LXRS and FXR: the yin and yang of cholesterol and fat metabolism.

  2006cited by this paper
• Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.

  2004cited by this paper
• Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation Published, JLR Papers in Press, September 16, 2003. DOI 10.1194/jlr.M300215-JLR200

  2004cited by this paper
• Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.

  2003cited by this paper
• Identification of Gene-selective Modulators of the Bile Acid Receptor FXR*

  2003cited by this paper
• 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

  2002cited by this paper
• Redundant pathways for negative feedback regulation of bile acid production.

  2002cited by this paper
• The Structural Basis for the Specificity of Retinoid-X Receptor-selective Agonists: New Insights Into the Role of Helix H12*

  2002cited by this paper
• Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor*

  2001cited by this paper
• Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors.

  2000cited by this paper
• A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.

  2000cited by this paper
• Identification of a chemical tool for the orphan nuclear receptor FXR.

  2000cited by this paper
• Bile acids: natural ligands for an orphan nuclear receptor.

  1999cited by this paper
• Identification of a nuclear receptor for bile acids.

  1999cited by this paper
• Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.

  1999cited by this paper
• Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain.

  1998cited by this paper
• Raf and Mitogen-activated Protein Kinase Regulate Stellate Cell Collagen Gene Expression (*)

  1996cited by this paper

• Structural insights into molecular and cellular level FXR binding potentials of GW4064 and LY2562175 hybrids by multi in silico modelling analyses

  2025cites this paper
• Multicomponent Cocrystals of 4-Chloro-3-sulfamoylbenzoic Acid with Carboxamides and Pyridine N -Oxides

  2025cites this paper
• The Role of Five‐Membered Aromatic Rings Containing N and O in Modulating Bile Acid Receptors: An Overview

  2025cites this paper
• Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators.

  2022cites this paper
• Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.

  2020cites this paper
• Bile-ology: from bench to bedside

  2019cites this paper
• Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study.

  2018cites this paper
• FARNESOID X RECEPTOR (FXR): A VERSATILE BILE ACID RESPONSIVE ELEMENT: A MOLECULAR BASIS OF REVIEW

  2018cites this paper
• Structure-function studies of β-lactamases

  2018cites this paper
• Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning

  2018cites this paper
• Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators

  2018cites this paper
• Binding free energy predictions of farnesoid X receptor (FXR) agonists using a linear interaction energy (LIE) approach with reliability estimation: application to the D3R Grand Challenge 2

  2017cites this paper
• Workflows and performances in the ranking prediction of 2016 D3R Grand Challenge 2: lessons learned from a collaborative effort

  2017cites this paper
• Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2

  2017cites this paper
• D3R Grand Challenge 2: blind prediction of protein–ligand poses, affinity rankings, and relative binding free energies

  2017cites this paper
• Modern drug design: the implication of using artificial neuronal networks and multiple molecular dynamic simulations

  2017cites this paper
• Performance of multiple docking and refinement methods in the pose prediction D3R prospective Grand Challenge 2016

  2017cites this paper
• Impact of domain knowledge on blinded predictions of binding energies by alchemical free energy calculations

  2017cites this paper
• 9. The Systems Biology of Transporters – Targeting the Regulatory System for Transporters (FXR/RXR)

  2017cites this paper
• Combining self- and cross-docking as benchmark tools: the performance of DockBench in the D3R Grand Challenge 2

  2017cites this paper
• Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations

  2017cites this paper
• CDOCKER and $$\lambda$$λ-dynamics for prospective prediction in D3R Grand Challenge 2

  2017influential citation
• Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases.

  2016cites this paper
• Role of farnesoid X receptor in cholestasis

  2016cites this paper
• Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.

  2016cites this paper
• Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism

  2015cites this paper
• NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor

  2015cites this paper
• Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.

  2015cites this paper
• Web-based Computational Tools Used in Protein Surface Analysis and Characterization. Applications for Protein–Protein and Protein–Ligand Interactions

  2015cites this paper
• Molecular Modeling Assisted Design and Synthesis of Unsymmetrical Anthracene Isoxazole Small Molecule Anti-tumor Agents

  2015cites this paper
• Farnesoid X receptor and reproduction

  2014cites this paper
• Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities.

  2014cites this paper
• Characterizing ligands for farnesoid X receptor – available in vitro test systems for farnesoid X receptor modulator development

  2014cites this paper
• Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands.

  2014cites this paper
• Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists.

  2014cites this paper
• Identification of liver X receptor and farnesoid X receptor dual agonists from Tithonia diversifolia

  2013cites this paper
• Asymmetric synthesis of the four diastereoisomers of a novel non-steroidal farnesoid X receptor (FXR) agonist: role of the chirality on the biological activity.

  2013cites this paper
• FXR signaling in the enterohepatic system.

  2013cites this paper
• Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.

  2012cites this paper
• Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.

  2012cites this paper
• Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.

  2012cites this paper
• Simultaneous diastereo- and enantioseparation of farnesoid X receptor (FXR) agonists with a quinine carbamate-based chiral stationary phase

  2012cites this paper
• Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene.

  2011cites this paper
• Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.

  2011cites this paper
• Bile Acid Receptor Modulators in Metabolic Diseases

  2011cites this paper
• Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum

  2011cites this paper
• Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.

  2011cites this paper
• Sulfonamide−Pyridine-N-oxide Cocrystals

  2011cites this paper
• Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation

  2011cites this paper
• Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription.

  2010cites this paper
• Farnesoid X receptor modulators: a patent review

  2010cites this paper
• Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.

  2010cites this paper
• Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment.

  2010cites this paper
• Free Energy Perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D 3 R Grand Challenge

  year unknowninfluential citation